Home » NOVEL THERAPEUTIC CANDIDATE IDENTIFIED THROUGH PHARMACOPEIA COLLABORATION ENTERS PRECLINICAL DEVELOPMENT
NOVEL THERAPEUTIC CANDIDATE IDENTIFIED THROUGH PHARMACOPEIA COLLABORATION ENTERS PRECLINICAL DEVELOPMENT
Pharmacopeia, an innovator in the discovery and development of novel small molecule therapeutics, today announced that a compound identified through the Company's ongoing collaboration with Schering-Plough, has been selected by Schering-Plough for preclinical development. The compound is being evaluated as a potential treatment for metabolic diseases.
PR
Newswire
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May